<DOC>
	<DOCNO>NCT00432354</DOCNO>
	<brief_summary>The aim study determine whether atorvastatin 40mg per day effective treatment SLE .</brief_summary>
	<brief_title>An Open Labeled Pilot Study Atorvastatin Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Background : Statins lipid-lower agent pleiotropic effect . Beyond traditional effect inhibitor 3-hydroxy-3methylglytaryl coenzyme A ( HMG-CoA ) reductase , anti-inflammatory immunomodulatory property . The administration atorvastatin lupus-prone model NZB/W F1 mouse result significant reduction serum IgG anti-dsDNA Abs decrease proteinuria . In pilot study three patient SLE , simvastatin induce rapid significant reduction proteinuria level . However , randomize double-blinded placebo-controlled study pending . Objective : The goal study evaluate clinical efficacy laboratory effect atorvastatin SLE . Methods : Forty patient SLE randomize two group receive atorvastatin adjuvant immunosuppressive agent therapy . Patients receive atorvastatin 6 month stop atorvastatin 8 week washout period . We cross placebo experimental group , give atorvastatin another 6 month . Primary outcome improvement lupus disease status measure SLEDAI microcirculation improvement via nailfold capillaroscopy .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . 16–80 year age , fulfil ACR criterion classification SLE ( limit disease duration ) 2 . Active disease status include ( 1 ) active nephritis moderate proteinuria ( 1.0gm/day 2.5gm/day ) despite ongoing immunosuppressive therapy ( 2 ) moderate active extrarenal component SLEDAI score range 3 10 . The SLEDAI score stable least two week prior screen . 3 . The type number immunosuppressive agent change recent one month 1. inability give informed consent ; 2. myositis ( CK &gt; 3×normal value ) ; 3. dialysis serum creatinin &gt; 2.5mg/dL ; 4. abnormal liver function ( ALT &gt; 3×normal value ) ; 5. pregnant breastfeeding ; 6. lifethreatening illness would interfere ability complete study ; 7. current drug alcohol abuse 8 . Already statin therapy 9 . Active SLE disease need add new immunosuppressive agent increase current drug dosage 50 % .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>statin</keyword>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>microcirculation</keyword>
</DOC>